Skip to main
HOTH

Hoth Therapeutics (HOTH) Stock Forecast & Price Target

Hoth Therapeutics (HOTH) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Hoth Therapeutics is a potential buy for investors due to its strategically diversified pipeline and positive clinical data, including support for continued development and dose optimization for the topical cancer treatment, HT-001. Upcoming catalysts, such as phase II trial approvals and potential data readouts from the CLEER-001 study, could drive further growth for the company. However, investors should also consider potential risks, including clinical/regulatory, financial, commercial, and legal risks that could impact the company's progress.

Bears say

Hoth Therapeutics is a high-risk investment due to the early stage of its drug development programs, lack of controlled efficacy data, and reliance on partnerships for funding. Additionally, potential competitors and the complexity of obtaining regulatory approval for new drugs pose further risks to the company's success.

Hoth Therapeutics (HOTH) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Hoth Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Hoth Therapeutics (HOTH) Forecast

Analysts have given Hoth Therapeutics (HOTH) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Hoth Therapeutics (HOTH) has a Strong Buy consensus rating as of May 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $5, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $5, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Hoth Therapeutics (HOTH)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.